GlassScriptPhysician profile
Paul Clarke Thomas
NPI 1780770842
$13,472.21
in general payments reported to CMS, 2019-2025
47 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $1,379 · 2021: $2,584 · 2022: $2,177 · 2023: $1,719 · 2024: $2,415 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,304.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,846.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,789.21 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,509.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,397.09 | 2019-2025 | |
| Lilly USA, LLC | $879.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $617.46 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.23 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $451.52 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $424.23 | 2020-2025 | Eliquis, Camzyos |
| Amgen INC. | $389.55 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Esperion Therapeutics, INC. | $292.31 | 2021-2024 | Nexletol |
| Amarin Pharma, INC. | $239.25 | 2019-2021 | |
| Allergan, INC. | $237.18 | 2019-2020 | |
| Astellas Pharma US INC | $232.77 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $215.89 | 2019-2023 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.